Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors
irradiation
+ radiosurgery
Enfermedades del Cerebro+7
+ Enfermedades del Sistema Nervioso Central
+ Enfermedades y Anomalías Congénitas, Hereditarias y Neonatales
Estudio de Tratamiento
Resumen
Fecha de inicio: 1 de noviembre de 1994
Fecha en la que se inscribió al primer participante.PROTOCOL OUTLINE: This is a randomized study. Tumor size and number are confirmed prior to randomization. Patients are stratified by participating institution. Patients are randomly assigned to 1 of 2 treatment groups. One group is treated with fractionated whole-brain irradiation using megavoltage equipment. The second group receives stereotactic radiosurgery plus fractionated whole-brain radiotherapy. Stereotactic radiosurgery involves irradiation of all tumors to the margins on stereotactic computerized tomography or magnetic resonance imaging. Either treatment may be administered first; the second treatment begins within 1 month of the first. Concurrent anticonvulsants and steroids are allowed. Patients are followed for change in size and number of tumors at 1, 3, and 6 months; follow-up clinical exams are performed at least every 2 months.
Protocolo
Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.Se reclutarán 40 pacientes
Número total de participantes que el ensayo clínico espera reclutar.Estudio de Tratamiento
Elegibilidad
Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.Cualquier sexo
Sexo biológico de los participantes elegibles para inscribirse.Voluntarios sanos no permitidos
Indica si personas sanas, sin la condición que se estudia, pueden participar.Condiciones
Patología
Criterios
Multiple newly diagnosed brain tumors Histologic confirmation of carcinoma at primary or metastatic site Tumors less than 25 mm mean diameter and more than 5 mm from optic chiasm No more than 4 tumors on magnetic resonance imaging Systemic disease controlled Neurologic function preserved Radiographic staging within 2 months of randomization required Performance status: Karnofsky 70%-100%